Connolly SJ, Crowther M, Eikelboom JW, ANNEXA-4 Investigators, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsivgoulis G, Wilson D, Katsanos AH, et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol. 2018;84(5):694–704. https://doi.org/10.1002/ana.25342. (Epub 2018 Oct 25).

Article  CAS  PubMed  Google Scholar 

Demchuk AM, Yue P, Zotova E, ANNEXA-4 Investigators, et al. Hemostatic efficacy and anti-FXa (Factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy. Stroke. 2021;52(6):2096–105. https://doi.org/10.1161/STROKEAHA.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strein M, May S, Brophy GM. Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants. Curr Opin Crit Care. 2020;26(2):122–8. https://doi.org/10.1097/MCC.0000000000000706.

Article  PubMed  Google Scholar 

Christensen H, Cordonnier C, Kõrv J, et al. European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J. 2019;4(4):294–306.

Article  PubMed  PubMed Central  Google Scholar 

Steffel J, Collins R, Antz M, et al., External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–76.

Greenberg SM, Ziai WC, Cordonnier C, et al, American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282–361. https://doi.org/10.1161/STR.0000000000000407.

Moher D, Liberati A, Tetzlaff J, et al, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(24):2987–3001. https://doi.org/10.1016/j.jacc.2021.04.061.

Article  CAS  PubMed  Google Scholar 

Culbreth SE, Rimsans J, Sylvester K, et al. Andexanet alfa—the first 150 days. Am J Hematol. 2019;94(1):E21–4. https://doi.org/10.1002/ajh.25326. (Epub 2018 Nov 26).

Article  PubMed  Google Scholar 

Ammar AA, Ammar MA, Owusu KA, et al. Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage. Neurocrit Care. 2021;35(1):255–61. https://doi.org/10.1007/s12028-020-01161-5. (Epub 2021 Jan 6).

Article  CAS  PubMed  Google Scholar 

Barra ME, Das AS, Hayes BD, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. 2020;18(7):1637–47. https://doi.org/10.1111/jth.14838. (Epub 2020 May 12).

Article  CAS  PubMed  Google Scholar 

Khadka S, Kasireddy V, Dhakal P. Institutional experience of using andexanet alfa. Cureus. 2020;12(7):e9173. https://doi.org/10.7759/cureus.9173.

Article  PubMed  PubMed Central  Google Scholar 

Vestal ML, Hodulik K, Mando-Vandrick J, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis. 2022;53(1):167–75. https://doi.org/10.1007/s11239-021-02495-3. (Epub 2021 Jun 8).

Article  CAS  PubMed  Google Scholar 

Stevens VM, Trujillo TC, Kiser TH, et al. Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding. Clin Appl Thromb Hemost. 2021;27:10760296211039020. https://doi.org/10.1177/10760296211039020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradshaw PG, Keegan S, Foertsch M, et al. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. J Thromb Thrombolysis. 2022;54(2):295–300. https://doi.org/10.1007/s11239-022-02658-w. (Epub 2022 May 4).

Article  CAS  PubMed  Google Scholar 

Davis SEB, Dehne KA, Rubinos CA, et al. Difficulties detecting clinically relevant factor Xa inhibitor levels prior to reversal with andexanet alfa for intracranial hemorrhage. Neurohospitalist. 2022;12(2):276–9. https://doi.org/10.1177/19418744211048013. (Epub 2021 Sep 24).

Article  PubMed  Google Scholar 

Milioglou L, Liao K, Traeger J, et al. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre. Blood Coagul Fibrinolysis. 2022;33(5):261–5. https://doi.org/10.1097/MBC.0000000000001128. (Epub 2022 Mar 7).

Article  CAS  PubMed  Google Scholar 

Morton C, Lista A, Jakowenko N, et al. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. J Thromb Thrombolysis. 2022;53(1):235–9. https://doi.org/10.1007/s11239-021-02521-4. (Epub 2021 Jul 8).

Article  CAS  PubMed  Google Scholar 

Parsels KA, Seabury RW, Zyck S, et al. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: a single-center, retrospective, matched cohort analysis. Am J Emerg Med. 2022;55:16–9. https://doi.org/10.1016/j.ajem.2022.02.036. (Epub 2022 Feb 24).

Article  PubMed  Google Scholar 

Rauch S, Müller HP, Dreyhaupt J, et al. Andexanet alfa for reversal of factor Xa inhibitors in intracranial hemorrhage: observational cohort study. J Clin Med. 2022;11(12):3399. https://doi.org/10.3390/jcm11123399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blackburn M. Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa. Am J Emerg Med. 2022. https://doi.org/10.1016/j.ajem.2022.08.041. (Epub ahead of print).

Article  PubMed  Google Scholar 

Bradshaw PG, Keegan SP, Droege ME, et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy. 2022;42(10):780–91. https://doi.org/10.1002/phar.2727. (Epub 2022 Sep 23).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown CS, Scott RA, Sridharan M, et al. Real-world utilization of andexanet alfa. Am J Emerg Med. 2020;38(4):810–4. https://doi.org/10.1016/j.ajem.2019.12.008. (Epub 2019 Dec 10).

Article  PubMed  Google Scholar 

Schmidt LE, Hinton MS, Martin ND. Real-world reversal of factor Xa inhibition in the setting of major life-threatening bleeding or urgent surgery. J Pharm Pract. 2022. https://doi.org/10.1177/08971900221125516. (Epub ahead of print).

Article  PubMed  Google Scholar 

Giovino A, Shomo E, Busey KV, et al. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2020;195:106070. https://doi.org/10.1016/j.clineuro.2020.106070.

Article  PubMed  Google Scholar 

Abdulrehman J, Eikelboom JW, Siegal DM. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiol. 2019;15(6):395–404. https://doi.org/10.2217/fca-2019-0038. (Epub 2019 Oct 31).

Article  CAS  PubMed  Google Scholar 

Abuan I, Wong KH, Bolinske B, et al. Andexanet alfa: a recombinant modified human factor Xa protein for drug reversal of rivaroxaban and apixaban. J Pharm Technol. 2019;35(3):119–25. https://doi.org/10.1177/8755122519839437. (Epub 2019 Mar 28).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol. 2019;94(6):697–709. https://doi.org/10.1002/ajh.25475.

Article  PubMed  Google Scholar 

Carpenter E, Singh D, Dietrich E, et al. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf. 2019;26(10):2042098619888133. https://doi.org/10.1177/2042098619888133.

Article  Google Scholar 

Cervi A, Crowther M. Andexanet alfa for the treatment of hemorrhage. Expert Rev Hematol. 2018;11(11):847–55. https://doi.org/10.1080/17474086.2018.1532287. (Epub 2018 Oct 17).

Article  CAS  PubMed  Google Scholar 

Favresse J, Hardy M, van Dievoet MA, et al. Andexanet alfa for the reversal of factor Xa inhibitors. Expert Opin Biol Ther. 2019;19(5):387–97. https://doi.org/10.1080/14712598.2019.1599355. (Epub 2019 Apr 11).

Article  CAS  PubMed  Google Scholar 

Heo YA. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049–55. https://doi.org/10.1007/s40265-018-0940-4. (Erratum in: Drugs. 2018 Aug;78(12):1285).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nederpelt CJ, Naar L, Krijnen P, et al. Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis. Crit Care Med. 2021;49(10):e1025–36. https://doi.org/10.1097/CCM.0000000000005059.

Article  CAS  PubMed  Google Scholar 

Powell J, Taylor J, Garland SG. Andexanet alfa: a novel factor Xa inhibitor reversal agent. Ann Pharmacother. 2019;53(9):940–6. https://doi.org/10.1177/1060028019835209. (Epub 2019 Feb 27).

Article  CAS  PubMed  Google Scholar 

Shrestha DB, Budhathoki P, Adhikari A, et al. Efficacy and safety of andexanet alfa for bleeding caused by factor Xa inhibitors: a systematic review and meta-analysis. Cureus. 2021;13(12):e20632. https://doi.org/10.7759/cureus.20632.

Article  PubMed  PubMed Central  Google Scholar 

Sible AM, Nawarskas JJ. Andexanet alfa for reversing factor Xa inhibition. Cardiol Rev. 2019;27(2):108–11. https://doi.org/10.1097/CRD.0000000000000230.

Article  PubMed  Google Scholar 

Ellington TM. A systematic and evidence-based review of published and pending reports of andexanet alfa. J Pharm Pract. 2020;33(4):465–70. https://doi.org/10.1177/0897190018822556. (Epub 2019 Jan 6).